0000000000056217

AUTHOR

Manuel Anguita

showing 5 related works from this author

Variables affecting the quality of anticoagulation in atrial fibrillation patients newly initiating vitamin K antagonists: insights from the national…

2021

Abstract Aims Vitamin K antagonists (VKAs) are effective drugs reducing the risk for stroke in atrial fibrillation (AF), but the benefits derived from such therapy depend on the international normalized ratio (INR) maintenance in a narrow therapeutic range. Here, we aimed to determine independent variables driving poor anticoagulation control [defined as a time in therapeutic range (TTR) <65%] in a ‘real world’ national cohort of AF patients. Methods and results The SULTAN registry is a multicentre, prospective study, involving patients with non-valvular AF from 72 cardiology units expert in AF in Spain. At inclusion, all patients naïve for oral anticoagulation were started with VKAs…

Malemedicine.medical_specialtyVitamin K030204 cardiovascular system & hematologyAmiodaroneCoronary artery disease03 medical and health sciences0302 clinical medicinePhysiology (medical)Internal medicineAtrial FibrillationHumansMedicineInternational Normalized RatioProspective StudiesRegistries030212 general & internal medicineProspective cohort studyStrokeAgedAged 80 and overbusiness.industryProportional hazards modelAnticoagulantsAtrial fibrillationOdds ratioMiddle Agedmedicine.diseaseConfidence intervalStrokeFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugEP Europace
researchProduct

Sex differences in the management of patients with acute coronary syndrome: A population-based ecological cross-sectional study in Spain

2021

Abstract Introduction and objectives Despite evidence of a reduction in the incidence and mortality of acute coronary syndrome (ACS), some studies have highlighted differences in outcomes between men and women. We aimed to explore sex differences in the management and treatment of patients with ACS in Spain. Methods This ecological cross-sectional study combined ACS data from 10 Spanish registries (54 centres). Meta-regression analysis was performed using aggregated data of baseline characteristics, interventional procedures, treatments, and events that occurred during hospitalization and one-year follow-up. Results Aggregated data from 34 605 patients (75.1% men) was included. ST-segment e…

Acute coronary syndromePercutaneousRevascularization surgerybusiness.industryEcologyCross-sectional studyIncidence (epidemiology)medicine.diseaseDiabetes mellitusmedicineMyocardial infarctionCardiology and Cardiovascular MedicinebusinessKillip classREC: CardioClinics
researchProduct

Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH…

2018

During the last few years, the number of patients receiving anticoagulant and antiplatelet therapy has increased worldwide. Since this is a chronic treatment, patients receiving it can be expected to need some kind of surgery or intervention during their lifetime that may require treatment discontinuation. The decision to withdraw antithrombotic therapy depends on the patient's thrombotic risk versus hemorrhagic risk. Assessment of both factors will show the precise management of anticoagulant and antiplatelet therapy in these scenarios. The aim of this consensus document, coordinated by the Cardiovascular Thrombosis Working Group of the Spanish Society of Cardiology, and endorsed by most o…

Malemedicine.medical_specialtymedicine.drug_classHemorrhage030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRisk FactorsThromboembolismIntervention (counseling)Preoperative CareAntithromboticmedicineHumans030212 general & internal medicineIntensive care medicineAgedAged 80 and overThrombotic riskIntraoperative CareDrug Substitutionbusiness.industryAnticoagulantAnticoagulantsGeneral MedicinePerioperativemedicine.diseaseThrombosisDiscontinuationConventional PCIFemaleAntiagregación Anticoagulación Anticoagulation Antiplatelet Antithrombotic Antitrombótico Cirugía SurgerybusinessPlatelet Aggregation InhibitorsRevista Española de Cardiología (English Edition)
researchProduct

Quality of Anticoagulation With Vitamin K Antagonists

2015

Background Vitamin K antagonists (VKA) have a narrow therapeutic range, and literature analysis reveals poor quality of anticoagulation control. We sought to assess the prevalence of poor anticoagulant control in patients under VKA treatment in the prevention of stroke for atrial fibrillation (AF). Hypothesis Control of anticoagulation with VKA is inadequate in a high percentage of patients with AF. Methods Patients with AF under VKA treatment were prospectively recruited in this observational registry. The sample comprised 948 patients. The estimated time spent in the therapeutic range (TTR) was calculated, and variables related with a TTR >65% were analyzed. Results Mean age was 73.8 ± 9.…

medicine.medical_specialtybusiness.industryAtrial fibrillationGeneral MedicineOdds ratiomedicine.diseaseLower riskComorbidityConfidence intervalSurgeryInternal medicinemedicineLiver functionCardiology and Cardiovascular MedicinebusinessProspective cohort studyStrokeClinical Cardiology
researchProduct

Tratamiento hipolipemiante en los pacientes con enfermedad cardiovascular de riesgo muy elevado. Documento de consenso SEC sobre las indicaciones de …

2021

Different primary and secondary prevention studies have documented that a greater degree of reduction in low-density lipoprotein cholesterol (LDL-C) levels is associated with a greater decrease in cardiovascular event rates. PCSK9 inhibitors achieve important, rapid and sustained decreases in LDL-C. New clinical practice guidelines for the management of dyslipidemia establish reduced target levels of LDL-C. These goals are hardly achievable with a statin-only treatment, even in combination with ezetimibe. The addition of PCSK9 inhibitors can play a determining role in achieving these recommendations. However, it is important to identify the patient subgroups that can most benefit from this …

Secondary preventionGynecologyCardiovascular eventmedicine.medical_specialtybusiness.industryPatient subgroupsmedicine.diseaseClinical PracticeEzetimibemedicinelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessPCSK9 InhibitorsDyslipidemiaLipoprotein cholesterolmedicine.drugREC: CardioClinics
researchProduct